We have previously reported that transforming growth factor β (TGF-β) triggers two independent senescence programs, 1) replicative senescence dependent upon telomere shortening and 2) premature senescence independent of telomere shortening, in the cell line of A549 human lung adenocarcinoma. In this study, we examined the possibility that cancer cell tumor phenotypes could be suppressed by forced senescence. We used A549 cells treated with TGF-β for a long time (over 50 days), where senescence was induced in a telomere-shortening-dependent or an independent way. Fully senescent A549 cells were elongated, acquired contact inhibition capabilities when reaching confluence, and secreted the senescence-associated cytokine IL-6. Furthermore, senescent A549 cells had no tumorigenicity in nude mice. These results indicate that the forced induction of senescence in cancer cells may be a novel and potentially powerful method for advancing anti-cancer therapy. © 2003 by Japan Society for Bioscience, Biotechnology, and Agrochemistry.
CITATION STYLE
Katakura, Y., Nakata, E., Tabira, Y., Miura, T., Teruya, K., Tsuchiya, T., & Shirahata, S. (2003). Decreased Tumorigenicity In Vivo When Transforming Growth Factor β Treatment Causes Cancer Cell Senescence. Bioscience, Biotechnology and Biochemistry, 67(4), 815–821. https://doi.org/10.1271/bbb.67.815
Mendeley helps you to discover research relevant for your work.